STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #498 by analyst upside · 2026-06-27
OBIO
Orchestra BioMed Holdings, Inc.
Healthcare · Market Cap $254M · P/E 0x
ANALYST PRICE TARGET
+186.9%
implied upside to consensus target
Current Price $4.24
Consensus Target $12.17
Bull Target $20.0
Bear Target $9.0
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
4
Hold
1
Sell
0
52-Week Low $2.2
52-Week High $5.42
YTD Return -1.6%
FUNDAMENTALS
Market Cap $254M
P/E Ratio (TTM) N/A
Forward P/E -2.9x
EPS (TTM) $-0.95
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $33M
Profit Margin -167.0%
52-WEEK RANGE
52-Week Low $2.2
52-Week High $5.42
Current Price $4.24
Bear Target $9.0
Bull Target $20.0
● Now $4.24 ● Target $12.17
TRADING DATA
Avg Volume 212K
YTD Return -1.6%
Analyst Count 6
Consensus Buy
Upside to Target +186.9%
Last Updated 2026-06-27

ANALYST SUMMARY

Orchestra BioMed Holdings, Inc. (OBIO) is currently trading at $4.24 with a Wall Street consensus price target of $12.17, implying potential upside of 186.9% over the next 12 months. 6 analysts currently cover OBIO, with a consensus rating of Buy - 86% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $20.0, while the most cautious has a target of $9.0.

OBIO operates in the Healthcare sector with a market capitalisation of $254M. The stock is down 1.6% year-to-date and is currently trading near the upper end of its 52-week range of $2.2 – $5.42.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for OBIO, with each firm's 90-day track record across all stocks we track. See full firm rankings →

B. Riley Securities — Reiterated
Buy → Buy 2026-05-19 17% win rate (6 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-05-14 31% win rate (48 calls)
Barclays — Reiterated
Overweight → Overweight 2026-05-13 Building track record
Chardan Capital — Reiterated
Buy → Buy 2026-03-12 33% win rate (6 calls)
Barclays — Reiterated
Overweight → Overweight 2026-01-09 Building track record
TD Cowen ● Initiated
Buy 2025-12-10 Building track record
Chardan Capital — Reiterated
Buy → Buy 2025-11-13 33% win rate (6 calls)
Barclays — Reiterated
Overweight → Overweight 2025-11-12 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
37
out of 100
Coverage depth
15/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →